Wuhan United Pharmacy

Wuhan United Pharmaceutical Co., Ltd., established in 1998 and headquartered in the Wuhan East Lake High-tech Development Zone, is a Chinese pharmaceutical company specializing in modern Chinese medicine and chemical drug development. The company is widely recognized for its flagship product, Shengxuening (生血宁片), a treatment for iron-deficiency anemia derived from silkworm excrement that utilizes sodium iron chlorophyllin as its active ingredient. In addition to hematology, the company has expanded its portfolio into neurology with Valerian extract capsules for insomnia and infectious diseases with Jinye Baidu granules. Wuhan United Pharmacy maintains a robust manufacturing infrastructure and an R&D system that integrates production, learning, and research through collaborations with academic institutions. Its business model focuses on high-tech, high-market-capacity products with long life cycles, positioning it as a key player in the specialized Chinese pharmaceutical market.